Benzinga | Apr 15, 2021 08:39AM EDT

OncoSec To Present Encore Interim Data From The KEYNOTE-695 Phase 2b Clinical Trial At 10th World Congress Of Melanoma

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO(tm) (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA(r) (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients at the 10th World Congress of Melanoma. This is an encore presentation of data presented at The Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting. Presenters will also discuss the therapeutic potential of OncoSec's DNA medicines platform to elicit robust anti-tumor immunity via intratumoral gene electrotransfer of TAVO plus CXCL9.